ProCE Banner Activity

CME

Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens

Video

This activity, Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens, will provide oncology clinicians with information on the most recent biomarkers and treatments for metastatic pancreatic cancer, expert recommendations for treatment selection and sequencing, and updated information on emerging biomarkers and targeted therapies for pancreatic cancer.

AGENDA
Welcome and Introductions
Guideline-based Management of Metastatic Pancreatic Cancer
Emerging Testing and Treatment Approaches for Metastatic Pancreatic Cancer
Q&A Session and Activity Roundup 

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: July 29, 2022

Expiration: July 29, 2023

No longer available for credit.

Share

Faculty

Michael Pishvaian

Michael Pishvaian, MD, PhD

Associate Professor
Department of Oncology
Director
Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center
Sibley Memorial Hospital
The Johns Hopkins University School of Medicine
Washington, DC

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

Provided by

Jointly provided by the Potomac Center for Medical Education and Rockpointe

ProCE Banner
ProCE Banner

Supporters

This program is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.

Bayer HealthCare Pharmaceuticals Inc.

Novartis Pharmaceuticals Corporation

Target Audience

The intended audience for this educational initiative is oncologists and other clinicians who manage patients with metastatic pancreatic cancer.

Learning Objectives

At the conclusion of this education, participants should be able to:

  • Evaluate patients with metastatic pancreatic cancer based on current guideline recommendations for imaging and testing

  • Select evidence-based treatments for patients with metastatic pancreatic cancer accounting for patient performance, comorbidities, and preferences

  • Effectively communicate with patients with metastatic pancreatic cancer regarding genetic testing, treatment goals and preferences, and clinical trials

  • Discuss the prognostic and predictive potentials of emerging genetic tests to inform treatment selection for patients with pancreatic cancer

  • Evaluate the safety and efficacy of emerging therapies for metastatic pancreatic cancer

Disclosure

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors, and content developers reported the following relevant financial relationships with ineligible companies:

Michael J. Pishvaian, MD, PhD: Consulting Fee: Astra Zeneca, Merck; Contracted Research: Arcus Bio, IDEAYA, Merck, Novartis, Pfizer, Repare Tx, Seattle Genetics, Takeda, Tesaro, Tizona; Honoraria: Novartis; Pfizer

Rachna Shroff, MD, MS: Consulting Fee: AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, Merck, QED, Servier, Taiho, Zymeworks; Contracted Research: Bayer, BMS, Bristol-Myers Squibb, Exelixis, IMV, LOXO, Novocure, NUCANA, Pieris, QED, Rafael, Seagen, Taiho; Speakers' Bureau: Servier

Planners and Managers

The planners and managers reported the following relevant financial relationships with ineligible companies: 

Chelsey Goins, PhD: Has no relevant financial relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies: 

Katie Propst, PhD: Has no relevant financial relationships

Instructions for Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Disclosure of Unlabeled Use

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses. 

Accreditation

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC credit or the evaluation, please email contact@potomacme.org.

ABIM MOC RECOGNITION STATEMENT



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
 
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

ABMS MOC APPROVAL STATEMENT



Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine